Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
ACTRIMS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Antibodies
1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade
• 24 Mar 2022
5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang
• 3 Apr 2022
1:21
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease
Tim Bartels
• 17 Mar 2022
1:51
Selecting treatment options for NMOSD
Michael Levy
• 3 Apr 2022
4:41
The role of neuroprotectors in stroke management
Ashfaq Shuaib
• 24 Mar 2022
4:07
ACTIMIS: Glenzocimab add-on therapy reduces hemorrhage and mortality in ischemic stroke
Mikael Mazighi
• 9 May 2022
1:28
Targeting IL-6 signaling in ischemic stroke
Marios K. Georgakis
• 5 May 2022
1:54
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline
Tiago Outeiro
• 18 Mar 2022
2:26
Recent hot-button issues in headache research at CONy 2022
Dimos-Dimitrios Mitsikostas
• 22 Mar 2022
4:26
New treatments for migraine: who, what, and when?
Jessica Ailani
• 11 Apr 2022
3:00
How to sequence treatments in migraine
Jessica Ailani
• 11 Apr 2022
8:46
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet
• 22 Mar 2022
3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana
• 28 Feb 2022
3:33
Study of real-world evidence in patients with PMS and RMS treated with ocrelizumab
Virginia Meca-Lallana
• 28 Feb 2022
14:28
Advantages of oral anti-CGRP drugs in migraine prevention
Sait Ashina
• 17 Mar 2022
2:52
Impact of ocrelizumab disruption on RRMS
Kelly Cotchett
• 25 Feb 2022
1
2
3
4
5
…
10
Next